Azathioprine Response: TPMT, NUDT15 and Drug Dosing

Azathioprine is a widely used immunosuppressive drug, often prescribed for the management of inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and autoimmune hepatitis. However, not all patients respond to azathioprine in the same way, and some may even experience adverse effects. Genetic testing has emerged as a valuable tool in understanding and predicting individual responses to azathioprine. In this article, we will explore the role of genetic testing in the diagnosis and management of azathioprine response.

Unraveling the Mystery of Azathioprine Response

Azathioprine works by suppressing the immune system, thereby reducing inflammation and preventing tissue damage in autoimmune diseases. However, the response to azathioprine can vary significantly between individuals. Some patients may experience a significant improvement in their symptoms, while others may not respond at all, or even suffer from side effects such as fever, cytomegalovirus infection, or liver toxicity (1, 2, 3). The key to understanding these variable responses lies in our genes.

Genetic Factors Influencing Azathioprine Response

For azathioprine, two genes have guideline supported roles in dosing and toxicity assessment: TPMT and NUDT15. Variants in these genes lower the activity of the enzymes that break down azathioprine's active products, which raises the risk of serious low blood counts, so the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline recommends lower starting doses for some people (CPIC 2025 update). Other genes, including ITPA, GST and MRP4/ABCC4, have been studied, but these are research findings and do not have the same guideline supported role in dosing (2, 4). Knowing TPMT and NUDT15 status before treatment lets healthcare providers adjust the starting dose accordingly.

Uses of Genetic Testing for Azathioprine Response

Genetic testing for azathioprine response can be beneficial in several ways:

1. Personalized Treatment Plans

By checking TPMT and NUDT15 status, healthcare providers can choose a safer starting dose of azathioprine or consider alternative treatments for people at a higher risk of serious side effects (2, 4).

2. Early Identification of Potential Side Effects

Genetic testing of TPMT and NUDT15 can help identify patients who are at an increased risk of serious side effects from azathioprine, such as severe drops in blood counts. This allows healthcare providers to monitor these patients closely and take appropriate action, such as adjusting the dose or switching to an alternative treatment (1, 3).

3. Improved Patient Outcomes

Ultimately, the use of genetic testing for azathioprine response can lead to improved patient outcomes by ensuring that individuals receive the most effective treatment with the least risk of side effects. This can result in better disease management, a higher quality of life, and potentially reduced healthcare costs in some settings (2, 4, 5).

Conclusion

Genetic testing for azathioprine response holds great promise in the management of autoimmune diseases. By understanding the genetic factors that influence an individual's response to azathioprine, healthcare providers can create personalized treatment plans that optimize efficacy while minimizing the risk of side effects. As our understanding of the genetic basis of azathioprine response continues to grow, so too will our ability to harness this information to improve patient outcomes and revolutionize the treatment of autoimmune diseases.